|
Dear Editor-in-chief
Heat
therapy is commonly used to treat injured muscles, and recently, hyperthermia
which has been used in oncology was introduced as a modality for use in
sports medicine. The important physiological response which produces most
of the beneficial effects of hyperthermia is increased blood flow (Sekins
et al., 1984).
Effective clinical response occurs when the temperature reaches 41 to
45 °C (Lehmann and de Lateur, 1982),
increasing blood flow up to 15 times (Song, 1984).
Sekins et al., 1984
reported that to produce observable variations in blood perfusion, temperature
must rise above 41.5 °C as fast as possible. While there are several heating
modalities, studies have shown that electromagnetic waves are more effective
than other thermal modalities for treating injured muscles at depth of
1-4cm (Giombini et al., 2007).
However, because of lack of research-based evidence of the microwave hyperthermia
treatment, clinical and research studies need to be completed to confirm
the therapeutic effectiveness of hyperthermia. We recently reported that
hyperthermia treatment with a 434-MHz microwave and direct- contact applicator
increased and maintained the muscle temperature locally by 6.3-11.4°C
without causing muscle damage (Ichinoseki-Sekine et al., 2007).
This system has also been found to be a highly innovative and reliable
modality for treating acute muscle injuries (Giombini et al., 2001).
However, most of the hyperthermia systems commonly used in clinical situations
is equipped with a 2450-MHz microwave generator and a non-contact applicator.
The possibility exists that the muscle temperature is influenced by the
frequency and applicator style. Thus, the aim of this study was to investigate
the changes in human muscle temperature induced by two different types
of microwave hyperthermia systems. Our results could assist to solve the
lack of research-based evidence for the clinical effectiveness of hyperthermia
treatment.
In this study two different microwave hyperthermia systems were used.
One was a direct- contact microwave hyperthermia device (ALBA Hyperthermia
System, Restek SRL, Rome, Italy) equipped with a 434-MHz microwave generator
having a curve-shaped microstrip antenna applicator, and a silicon bolus
filled with thermostatic water. The skin temperature was automatically
controlled by a decrease/increase in the power output to maintain the
skin pilot temperature. The microwave power source was set to turn on/off
periodically as the default setting, and the temperature data were measured
during the power-off phase. The other device was a non-contact microwave
device (Microtizer, MT-SDi, Minato Medical Co. Ltd., Osaka, Japan) equipped
with a 2450-MHz microwave applicator including a helical antenna. This
system does not contain any temperature measurement system, and the skin
temperature was maintained manually by reducing the power output or varying
the distance between the applicator and skin surface. The settings of
both hyperthermia systems were established in accordance with the manufacturers'
instructions. The 434-MHz system was set with a power of 60 W, a skin
baseline temperature of 40°C,
and a bolus water temperature of 38°C.
The applicator was placed on the lateral side of one thigh, and the center
of the applicator position was adjusted to the position of the thermocouple.
The 2450-MHz system was set with a power of 150 W, and the distance between
the skin surface and applicator was approximately 15 cm. The skin and
muscle temperatures were measured using a digital thermometer (PTW-301,
Unique Medical, Tokyo, Japan) every 3 min for 10 s during the power-off
phase, and the center of the applicator position was adjusted to the position
of the thermocouple.
Eleven healthy adult males (24.3 ± 2.2 years, 1.74 ± 0.06 m, 70.0 ± 5.3
kg; mean ± SD) participated in this study. The subjects were placed in
the supine position and underwent 30 min of hyperthermia treatment with
either the 434 or 2450-MHz system on different days. At least 1 week elapsed
between the two measurements. All procedures described in this study were
performed with the approval of the Juntendo University Human Ethics Committee
and complied with the Declaration of Helsinki. All subjects gave written
informed consent. The thermocouple for determining the skin temperature
was placed on the belly of the vastus lateralis muscle. After anesthesia
with a 60% lidocaine tape (Penles, Wyeth K.K., Tokyo, Japan), a 23-G thermocouple
(IT-23, Physitemp Instruments, Clifton, NJ) was inserted into the muscle,
and its temperature at a depth of 2.0 ± 0.2 cm was measured. The room
temperature and humidity were controlled at 24.5 ± 0.3°C
and 51.6 ± 8.9%, respectively. In addition, to determine the depth of
the maximum heating point, we evaluated the vertical heating pattern using
a muscle equivalent phantom (Okano, et al., 2000).
After microwaves were applied, the temperature distribution on the vertical
cutting surface of the phantom was recorded immediately using a thermal
camera (Thermo Tracer TH71000, NEC San-ei Instruments, Tokyo, Japan).
As results, the muscle temperature with the 434-MHz system showed a single
peak at approximately 10 min. Significant differences were detected between
the systems in peak muscle temperature, temperature rise, and time to
peak temperature (p < 0.001; Table
1). The maximum heating point using the 434-MHz system (approximately
2 cm) was deeper than that of the 2450-MHz system (approximately 1 cm).
The peak skin temperatures were not significantly different between the
two systems.
However, the changes in muscle temperature did show different patterns;
a single peak at 10 min was seen with the 434-MHz system, whereas a slope
was observed with the 2450-MHz system. This behaviour with the 2450-MHz
system caused the substantial variation in the time to peak temperature.
In general, the therapeutic range for heat treatment in sports medicine
is assumed to be from 41 to 45ºC (Lehmann and de Lateur, 1982).
When the local muscle temperature first exceeds a threshold of 42 to 45ºC,
a rapid perfusion of cooling blood flow is induced in the high-temperature
region (Sekins et al., 1982).
This thermal washout reduces the temperature to prevent the muscle from
overheating. Our results suggest that the 434-MHz system increased the
muscle temperature to this therapeutic range and caused thermal washout.
However, some subjects could not reach the therapeutic range with the
2450-MHz system, and thermal washout might not have occurred because a
large temperature reduction was not observed. We showed that the radiation
frequency and applicator type of a microwave hyperthermia system influence
the change in human muscle temperature, but not skin temperature. According
to the phantom experiment results, the maximum heating point was shallow
in the 2450-MHz system; thus, the actual maximum temperature induced by
the 2450-MHz system might have been higher by 1ºC than our results. Even
so, the muscle temperature in some subjects may not have reached the temperature
necessary to cause thermal washout.
There are some studies that showed the benefits of hyperthermia at 434-MHz
system. Hyperthermia has benefits in acute muscle injuries, chronic overuse
tendinopathies and pain reduction (Giombini et al., 2002),
with short-term clinical improvement, good safety and no side effects.
The important physiological response which produces most of the beneficial
effects of hyperthermia is increased blood flow, and the effective clinical
response occurs when the temperature reaches 41 to 45ºC. Hyperthermia
produces an increase in nutrients and oxygen in the heated region, and
both two events are necessary to affect tissue repair. Our result showed
that 434-MHz hyperthermia system rapidly increases muscle temperature
to above 41ºC, and it support the previous reports.
To obtain the effect of hyperthermia treatment efficiently, both time
and temperature of application must be controlled. However, to our knowledge,
no study measured the changes in human muscle temperature induced by different
types of microwave hyperthermia systems. We believe that our results provided
research-based evidence for the clinical effectiveness of hyperthermia
treatment.
|
|